[go: up one dir, main page]

AR011907A1 - USE OF 4- (2,2-DIMETHYLPROPANOL) BUTANOIC ACID (PIVAGABIN) TO PREPARE A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FORMS OF DEPRESSIVE ANXIETY. - Google Patents

USE OF 4- (2,2-DIMETHYLPROPANOL) BUTANOIC ACID (PIVAGABIN) TO PREPARE A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FORMS OF DEPRESSIVE ANXIETY.

Info

Publication number
AR011907A1
AR011907A1 ARP980100917A ARP980100917A AR011907A1 AR 011907 A1 AR011907 A1 AR 011907A1 AR P980100917 A ARP980100917 A AR P980100917A AR P980100917 A ARP980100917 A AR P980100917A AR 011907 A1 AR011907 A1 AR 011907A1
Authority
AR
Argentina
Prior art keywords
forms
dimethylpropanol
prepare
treatment
pharmaceutical composition
Prior art date
Application number
ARP980100917A
Other languages
Spanish (es)
Original Assignee
A F S P A Aziende Chimiche Riunite Angelini Francesco A C R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A F S P A Aziende Chimiche Riunite Angelini Francesco A C R filed Critical A F S P A Aziende Chimiche Riunite Angelini Francesco A C R
Publication of AR011907A1 publication Critical patent/AR011907A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Utilizacion del ácido 4-(2,2-dimetilpropanol)butanoico para preparar una composicion farmacéutica para el tratamiento de formas de ansiedad depresiva.Entre las formas depresivas se pueden indicar las siguientes alteraciones del estado de ánimo,transtornos de ansiedad, transtornos somatoformes ytranstornos de adaptacion.Use of 4- (2,2-dimethylpropanol) butanoic acid to prepare a pharmaceutical composition for the treatment of forms of depressive anxiety. Among the depressive forms, the following mood disorders, anxiety disorders, somatoform disorders and disorders of adaptation.

ARP980100917A 1997-03-03 1998-03-02 USE OF 4- (2,2-DIMETHYLPROPANOL) BUTANOIC ACID (PIVAGABIN) TO PREPARE A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FORMS OF DEPRESSIVE ANXIETY. AR011907A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97MI000456A IT1290003B1 (en) 1997-03-03 1997-03-03 USE OF PIVAGABINA TO PREPARE PHARMACEUTICAL COMPOSITIONS

Publications (1)

Publication Number Publication Date
AR011907A1 true AR011907A1 (en) 2000-09-13

Family

ID=11376246

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100917A AR011907A1 (en) 1997-03-03 1998-03-02 USE OF 4- (2,2-DIMETHYLPROPANOL) BUTANOIC ACID (PIVAGABIN) TO PREPARE A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FORMS OF DEPRESSIVE ANXIETY.

Country Status (7)

Country Link
JP (1) JP2001513800A (en)
AR (1) AR011907A1 (en)
AU (1) AU7031798A (en)
IL (1) IL131355A0 (en)
IT (1) IT1290003B1 (en)
WO (1) WO1998038988A1 (en)
ZA (1) ZA981729B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031473A1 (en) * 2000-11-20 2003-09-24 Lundbeck & Co As H GABA INTENSIFIERS IN THE TREATMENT OF DISEASES RELATED TO A REDUCED NEUROSTEROID ACTIVITY
WO2008066874A1 (en) * 2006-11-30 2008-06-05 Cenerx Biopharma, Inc. Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders
EP3441382B1 (en) * 2016-04-05 2023-08-30 Moresco Corporation Oxa acid compound

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1202402B (en) * 1977-06-01 1989-02-09 Galzigna Lauro Hydrophobic derivs. of 4-aminobutyric acid

Also Published As

Publication number Publication date
ITMI970456A1 (en) 1998-09-03
IL131355A0 (en) 2001-01-28
IT1290003B1 (en) 1998-10-19
JP2001513800A (en) 2001-09-04
WO1998038988A1 (en) 1998-09-11
ZA981729B (en) 1998-08-28
AU7031798A (en) 1998-09-22

Similar Documents

Publication Publication Date Title
EE05419B1 (en) Substituted oxazolidinones for combination therapy
ES2165878T3 (en) USE OF MODAFINIL FOR THE TREATMENT OF SLEEP APNEAS AND VENTILATION DISORDERS OF CENTRAL ORIGIN.
ATE320184T1 (en) XYLITOL COMPOSITIONS FOR THE TREATMENT OF THE UPPER RESPIRATORY ORGANS
ATE365720T1 (en) AGONISTS OF BETA-ADRENORECEPTORS
ES2181614T3 (en) SULFONYL PHENYL HETEROCICLES REPLACED AS INHIBITORS OF CYCLOOXYGENASA-2 AND 5-LIPOXYGENASE.
EE05287B1 (en) The so-called clopentanoindoles, their use in the manufacture of a medicament and the pharmaceutical composition containing them
ES2186015T3 (en) DERIVATIVES OF 2- (PURIN-9-IL) -TETRAHIDROFURAN-3,4-DIOL.
AR029825A1 (en) A PHARMACEUTICALLY ACCEPTABLE COMPOSITION INCLUDING CARVEDILOL OR A SALT OF THE SAME PHARMACEUTICALLY ACCEPTABLE, A PROCEDURE FOR THE PRODUCTION OF SUCH COMPOSITION AND USE OF THE SAME
DK1361882T3 (en) 4-fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical
ECSP055609A (en) "Use of IkB-kinase inhibitors for the treatment of pain"
SE9701161D0 (en) New use I
AR012193A1 (en) NEW THERAPEUTIC COMBINATIONS
DK1315506T3 (en) Phospholipid derivatives of valproic acid and mixtures thereof
ES2150808T3 (en) CRYSTALLINE FORM OF (4-TRIFLUOROMETIL) -ANILIDA ACID 5-METHYLISOXAZOLE-4-CARBOXILICO.
AR020660A1 (en) ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF EYES, EARS AND NOSE
EE200400005A (en) A tablet containing at least two distinct segments and its use
ES2111175T3 (en) PIPERAZINES 1,4-DISSTITUTED USEFUL IN THE TREATMENT OF ASTHMA AND INFLAMMATION OF THE RESPIRATORY TRACT.
MX9701996A (en) UTILIZATION OF 3-OXO OF 2, 4-DIAMINO-PIRIMIDINE OR ONE OF ITS SALTS IN THE TREATMENT OF MATURATION DISORDERS AND COLLAGEN STRUCTURATION.
ES2064082T3 (en) BCRF1 PROTEINS AS INTERFERON-GAMMA INHIBITORS.
PA8525801A1 (en) PIRAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS TO MODULATE AND / OR INHIBIT THE ACTIVITY OF ERAB / HADH2
AR011907A1 (en) USE OF 4- (2,2-DIMETHYLPROPANOL) BUTANOIC ACID (PIVAGABIN) TO PREPARE A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FORMS OF DEPRESSIVE ANXIETY.
ES2125356T3 (en) USE OF LEFLUNOMIDE FOR INTERLEUKIN INHIBITION 8.
ES2163220T3 (en) DIOXACICLOALCAN-8-ONA.
AR021965A1 (en) USE OF INHIBITORS OF THE SODIUM-HYDROGEN EXCHANGER FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION OF THE DYSFUNCTION OF THE ORGANOSRELATED WITH THE AGE, OF THE DISEASES RELATED TO THE AGE AND FOR THE EXTENSION OF LIFE
AR037496A1 (en) NOVEDOUS USE OF 2- [5- (4-FLUOROPHENYL) -3-PIRIDILMETILAMINOMETIL] -CROMANO AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS